A 14 Day, Randomised, Double Blinded, Placebo-Controlled 2-Way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in an Environmental Exposition Unit (Vienna Challenge Chamber) in Subjects With Seasonal Allergic Rhinitis (SAR).

Trial Profile

A 14 Day, Randomised, Double Blinded, Placebo-Controlled 2-Way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in an Environmental Exposition Unit (Vienna Challenge Chamber) in Subjects With Seasonal Allergic Rhinitis (SAR).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs GSK 256066 (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Oct 2010 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
    • 12 Oct 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov.
    • 03 Dec 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top